anti shp1 ptpn6  (Boster Bio)

Journal: Cancers

Article Title: Evidence for a Tumor-Suppressive Role of SHP-1 in EMT Regulation in Bladder Cancer Cells

doi: 10.3390/cancers18091401

Figure Lengend Snippet: ( A ) Relative SHP-1 protein expression in the 19 BCa cell lines examined in this study. ( B ) Expression levels were significantly higher in epithelial-like cells (n = 11) than in intermediate and mesenchymal-like lines (n = 8). Error bars represent the standard error of the mean (SEM).

Article Snippet: Lentiviral shRNA constructs targeting SHP-1 were obtained from Origene (Rockville, MD, USA), and the manufacturer’s protocol was used to establish stable cell lines for each construct.

Techniques: Expressing

Journal: Cancers

Article Title: Evidence for a Tumor-Suppressive Role of SHP-1 in EMT Regulation in Bladder Cancer Cells

doi: 10.3390/cancers18091401

Figure Lengend Snippet: ( A ) SHP-1 protein expression in bladder tissue was significantly lower in muscle-invasive (MI, n = 8) tumor than in non-muscle-invasive (NMI, n = 8) and urothelial tissue with no residual disease (NRD, n = 10). ( B ) Examples of DAB and corresponding H&E staining in the bladder tissues examined in this study. The error bars represent the interquartile range.

Article Snippet: Lentiviral shRNA constructs targeting SHP-1 were obtained from Origene (Rockville, MD, USA), and the manufacturer’s protocol was used to establish stable cell lines for each construct.

Techniques: Expressing, Staining

Journal: Cancers

Article Title: Evidence for a Tumor-Suppressive Role of SHP-1 in EMT Regulation in Bladder Cancer Cells

doi: 10.3390/cancers18091401

Figure Lengend Snippet: Correlation plots (n = 19) of SHP-1 protein expression with the EMT markers E-cadherin, N-cadherin, and Vimentin. Gray areas represent the 95%CI. Representative Western blot images: from the BCa cell lines EJ and HT-1376, the first lane of each pair corresponds to the protein indicated above each lane, and the second corresponds to the total protein detected for the same lane.

Article Snippet: Lentiviral shRNA constructs targeting SHP-1 were obtained from Origene (Rockville, MD, USA), and the manufacturer’s protocol was used to establish stable cell lines for each construct.

Techniques: Expressing, Western Blot

Journal: Cancers

Article Title: Evidence for a Tumor-Suppressive Role of SHP-1 in EMT Regulation in Bladder Cancer Cells

doi: 10.3390/cancers18091401

Figure Lengend Snippet: ( A ) SHP-1 protein expression following transduction with SHP-1 shRNA (shSHP-1) or SHP-1 cDNA (+SHP-1) and corresponding negative controls (NC): CUBIII n = 6, RT-112 n = 7, TCCSUP n = 4, UM-UC-3 n = 6. ( B ) Representative Western blot images: the first lane of each pair corresponds to SHP-1, and the second corresponds to the total protein detected for the same lane. Error bars represent the SEM. ( C ) Relative proliferation rates of BCa cells transduced with SHP-1 shRNA (shSHP-1) or SHP-1 cDNA (+SHP-1) and corresponding negative controls (NC): CUBIII n = 5, RT-112 n = 5, TCCSUP n = 9, UM-UC-3 n = 5. Error bars represent the SEM.

Article Snippet: Lentiviral shRNA constructs targeting SHP-1 were obtained from Origene (Rockville, MD, USA), and the manufacturer’s protocol was used to establish stable cell lines for each construct.

Techniques: Expressing, Transduction, shRNA, Western Blot

Journal: Cancers

Article Title: Evidence for a Tumor-Suppressive Role of SHP-1 in EMT Regulation in Bladder Cancer Cells

doi: 10.3390/cancers18091401

Figure Lengend Snippet: ( A ) Relative migration rates of BCa cells transduced with SHP-1 shRNA (shSHP-1) or SHP-1 cDNA (+SHP-1) and corresponding negative controls (NC): CUBIII n = 5, RT-112 n = 4, TCCSUP n = 3, UM-UC-3 n = 3. ( B ) Representative images from in vitro migration assays (scale bar = 200 μm). ( C ) Relative invasion rates of BCa cells transduced with SHP-1 shRNA (shSHP-1) or SHP-1 cDNA (+SHP-1) and corresponding negative controls (NC): CUBIII n = 3, RT-112 n = 5, TCCSUP n = 3, UM-UC-3 n = 3. ( D ) Representative images from in vitro invasion assays (scale bar = 200 μm). Error bars represent the SEM.

Article Snippet: Lentiviral shRNA constructs targeting SHP-1 were obtained from Origene (Rockville, MD, USA), and the manufacturer’s protocol was used to establish stable cell lines for each construct.

Techniques: Migration, Transduction, shRNA, In Vitro

Journal: Cancers

Article Title: Evidence for a Tumor-Suppressive Role of SHP-1 in EMT Regulation in Bladder Cancer Cells

doi: 10.3390/cancers18091401

Figure Lengend Snippet: Significant gene sets resulting from GSEA of RNA sequence data comparing the transduced BCa lines with high-SHP-1-expressing lines versus low-SHP-1-expressing lines (q-value < 0.1).

Article Snippet: Lentiviral shRNA constructs targeting SHP-1 were obtained from Origene (Rockville, MD, USA), and the manufacturer’s protocol was used to establish stable cell lines for each construct.

Techniques: Sequencing, Expressing

Journal: Cancers

Article Title: Evidence for a Tumor-Suppressive Role of SHP-1 in EMT Regulation in Bladder Cancer Cells

doi: 10.3390/cancers18091401

Figure Lengend Snippet: Relative expression of pAkt/Akt in BCa cells transduced with SHP-1 shRNA (shSHP-1) or SHP-1 cDNA (+SHP-1) and corresponding negative controls (NC): RT-112 n = 7 and TCCSUP n = 8. Representative Western blot images: the first lane of each pair corresponds to Akt or pAkt (ser473), and the second corresponds to the total protein detected for the same lane. Error bars represent the SEM.

Article Snippet: Lentiviral shRNA constructs targeting SHP-1 were obtained from Origene (Rockville, MD, USA), and the manufacturer’s protocol was used to establish stable cell lines for each construct.

Techniques: Expressing, Transduction, shRNA, Western Blot

Journal: Current Issues in Molecular Biology

Article Title: Sodium Butyrate Ameliorated Bile Acid Metabolism in Diabetes Mellitus by PI3K/AKT Signaling Pathway via the Gut–Liver Axis

doi: 10.3390/cimb47090732

Figure Lengend Snippet: Monocellular barrier function analysis in CaCo 2 cells. Immunofluorescence assay for ( A ) ZO-1, ( B ) VE, ( C ) Occludin, ( D ) Claudin-5, ( G ) FXR, ( H ) PTPN6, and ( I ) GATA4 under a laser scanning confocal microscope, and fluorescence intensity was determined relative to each other. ( E ) The TEER of CaCo 2 cells was increased from Day 0 to Day 21; ( F ) Insulin + LPS increased transendothelial albumin passage across the monocellular barrier; ** p < 0.01, *** p < 0.001, vs. control (Day 0 or 0H). Intracellular content of TBA in ( J ) CaCo 2 was determined by kit; *** p < 0.001, n = 3.

Article Snippet: Primary antibodies against GPR43 (bs-13536R), PTPN6 (bs-4158R), GATA4 (bs-1778R), GLUT2 (bs-0351R), Insulin Receptor (bs-0681R), PI3K (bs-10657R), and p-PI3K (bs-6417R) were obtained from Bioss (Peking, China).

Techniques: Immunofluorescence, Microscopy, Fluorescence, Control

Journal: Current Issues in Molecular Biology

Article Title: Sodium Butyrate Ameliorated Bile Acid Metabolism in Diabetes Mellitus by PI3K/AKT Signaling Pathway via the Gut–Liver Axis

doi: 10.3390/cimb47090732

Figure Lengend Snippet: Effect of NaB on bile acid metabolism-related proteins in HepG 2 cells. Sodium butyrate (NaB) increased FXR, TGR5, PTPN6, GATA4, and CYP7A1 expression. Immunofluorescence assay for ( A ) FXR, ( B ) TGR5, ( C ) PTPN6, ( D ) GATA4, and ( E ) CYP7A1 under a laser scanning confocal microscope, and fluorescence intensity was determined relative to each other. ( F ) The above proteins were analyzed using Western blotting. The PI3K/AKT signaling pathway participated in the function of NaB. ( G ) WB detection of PI3K/AKT/GSK3 signaling proteins, including the ratio of p-PI3K to total PI3K, ratio of p-AKT to total AKT, and ratio of p-GSK3α to total GSK3α; ( E ) ratio of p-GSK3β to total GSK3β. * p < 0.05, ** p < 0.01, *** p < 0.001, vs. Ins + LPS, n = 3. shows the native image of the Western blot of .

Article Snippet: Primary antibodies against GPR43 (bs-13536R), PTPN6 (bs-4158R), GATA4 (bs-1778R), GLUT2 (bs-0351R), Insulin Receptor (bs-0681R), PI3K (bs-10657R), and p-PI3K (bs-6417R) were obtained from Bioss (Peking, China).

Techniques: Expressing, Immunofluorescence, Microscopy, Fluorescence, Western Blot

Journal: Discover Oncology

Article Title: Pan-cancer analysis of PTPN6: prognostic significance and functional implications in tumor progression

doi: 10.1007/s12672-025-03384-4

Figure Lengend Snippet: Immunohistochemical and immunofluorescence analysis of PTPN6 expression in different cancers tissues and cellular localization. A Human Protein Atlas-based immunohistochemical staining for PTPN6 in different cancer tissues: kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), and rectum adenocarcinoma (READ). B Schematic illustration of the predicted subcellular localization of PTPN6, highlighting detection in the nucleoplasm and nucleoli. C , D Immunofluorescence staining of PTPN6 in human cells showing its subcellular distribution. Green fluorescence indicates nuclear staining, while red fluorescence shows cytoskeletal structures

Article Snippet: A Human Protein Atlas-based immunohistochemical staining for PTPN6 in different cancer tissues: kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), and rectum adenocarcinoma (READ).

Techniques: Immunohistochemical staining, Immunofluorescence, Expressing, Staining, Fluorescence

Journal: Discover Oncology

Article Title: Pan-cancer analysis of PTPN6: prognostic significance and functional implications in tumor progression

doi: 10.1007/s12672-025-03384-4

Figure Lengend Snippet: Expression and methylation analysis of PTPN6 in different cancer types. A GEPIA2-based violin plots representing the expression levels of PTPN6 across different stages (I-IV) of kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), and rectum adenocarcinoma (READ). B OncoDB-based methylation beta values across different genomic regions of PTPN6 (promoter and gene body) in KIRC, LIHC, and READ. C UALCAN-based box plots comparing the promoter methylation levels of PTPN6 between normal and primary tumor samples in KIRC, LIHC, and READ, using data from The Cancer Genome Atlas (TCGA). D OncoDB-based box plots comparing the mRNA expression levels of PTPN6 between normal and primary tumor samples in KIRC, LIHC, and READ, using data from TCGA. P-value < 0.05

Article Snippet: A Human Protein Atlas-based immunohistochemical staining for PTPN6 in different cancer tissues: kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), and rectum adenocarcinoma (READ).

Techniques: Expressing, Methylation

Journal: Discover Oncology

Article Title: Pan-cancer analysis of PTPN6: prognostic significance and functional implications in tumor progression

doi: 10.1007/s12672-025-03384-4

Figure Lengend Snippet: Mutation analysis and impact on overall survival of PTPN6 in different cancer types. A cBioPortal-based oncoplots representing mutations in the PTPN6 gene in kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), and rectum adenocarcinoma (READ) across samples from The Cancer Genome Atlas (TCGA). B Kaplan-Meier survival curves showing the overall survival of patients with altered (red) versus unaltered (blue) PTPN6 in KIRC, LIHC, and READ. P-value < 0.05

Article Snippet: A Human Protein Atlas-based immunohistochemical staining for PTPN6 in different cancer tissues: kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), and rectum adenocarcinoma (READ).

Techniques: Mutagenesis

Journal: Discover Oncology

Article Title: Pan-cancer analysis of PTPN6: prognostic significance and functional implications in tumor progression

doi: 10.1007/s12672-025-03384-4

Figure Lengend Snippet: Correlation analysis of PTPN6 with immune-related gene signatures and different molecular. A TISIDB-based heatmaps showing the correlations of PTPN6 with immune-related genes, including immune inhibitors, MHC genes, and immune stimulators, across different cancers. B Violin plots displaying the expression levels of PTPN6 (log2CPM) across different molecular subtypes across three cancer types: Kidney Renal Clear Cell Carcinoma (KIRC), Liver Hepatocellular Carcinoma (LIHC), and Rectum Adenocarcinoma (READ). P-value < 0.05

Article Snippet: A Human Protein Atlas-based immunohistochemical staining for PTPN6 in different cancer tissues: kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), and rectum adenocarcinoma (READ).

Techniques: Expressing

Journal: Discover Oncology

Article Title: Pan-cancer analysis of PTPN6: prognostic significance and functional implications in tumor progression

doi: 10.1007/s12672-025-03384-4

Figure Lengend Snippet: Correlation of PTPN6 expression with diverse functional states of different cancer types. A CancerSEA-based heatmap showing the correlation between PTPN6 expression and 14 diverse functional states of different cancers. B Heatmap focusing on the correlation of PTPN6 expression with the same set of functional states in kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), and rectum adenocarcinoma (READ). P-value < 0.05

Article Snippet: A Human Protein Atlas-based immunohistochemical staining for PTPN6 in different cancer tissues: kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), and rectum adenocarcinoma (READ).

Techniques: Expressing, Functional Assay

Journal: Discover Oncology

Article Title: Pan-cancer analysis of PTPN6: prognostic significance and functional implications in tumor progression

doi: 10.1007/s12672-025-03384-4

Figure Lengend Snippet: Functional network and enrichment analysis of PTPN6-associated genes in cancer. A STRING-based protein-protein interaction (PPI) network of PTPN6 and its interacting proteins. B GO (Gene Ontology) enrichment analysis for cellular components. C GO enrichment analysis for molecular functions. D GO enrichment analysis for biological processes. E KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway enrichment analysis of PTPN6-associated genes. P-value < 0.05

Article Snippet: A Human Protein Atlas-based immunohistochemical staining for PTPN6 in different cancer tissues: kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), and rectum adenocarcinoma (READ).

Techniques: Functional Assay

Journal: Discover Oncology

Article Title: Pan-cancer analysis of PTPN6: prognostic significance and functional implications in tumor progression

doi: 10.1007/s12672-025-03384-4

Figure Lengend Snippet: PTPN6 expression correlates with immune infiltrates and drug sensitivity in different cancer types. A Correlation between PTPN6 expression and immune cell infiltrates in kidney renal clear cell carcinoma (KIRC). B Correlation between PTPN6 expression and immune cell infiltrates in liver hepatocellular carcinoma (LIHC). C Correlation between PTPN6 expression and immune cell infiltrates in rectum adenocarcinoma (READ). D Correlation between PTPN6 expression and drug sensitivity in the Genomics of Drug Sensitivity in Cancer (GDSC) dataset. P-value < 0.05

Article Snippet: A Human Protein Atlas-based immunohistochemical staining for PTPN6 in different cancer tissues: kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), and rectum adenocarcinoma (READ).

Techniques: Expressing

Journal: Discover Oncology

Article Title: Pan-cancer analysis of PTPN6: prognostic significance and functional implications in tumor progression

doi: 10.1007/s12672-025-03384-4

Figure Lengend Snippet: Comparison of PTPN6 gene expression in KIRC vs. normal control cell lines and the predictive power of PTPN6 for KIRC. A Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR)-based expression of PTPN6 gene in KIRC and normal control cell lines. B The Receiver Operating Characteristic (ROC) curve assesses the performance of PTPN6 expression as a predictive biomarker for distinguishing KIRC from normal tissue. P-value < 0.05

Article Snippet: A Human Protein Atlas-based immunohistochemical staining for PTPN6 in different cancer tissues: kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), and rectum adenocarcinoma (READ).

Techniques: Comparison, Gene Expression, Control, Reverse Transcription, Real-time Polymerase Chain Reaction, Quantitative RT-PCR, Expressing, Biomarker Discovery

Journal: Discover Oncology

Article Title: Pan-cancer analysis of PTPN6: prognostic significance and functional implications in tumor progression

doi: 10.1007/s12672-025-03384-4

Figure Lengend Snippet: Silencing PTPN6 reduces colony formation, proliferation, and wound healing in 786-O renal cancer cells. A) Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR)-based quantitative analysis of PTPN6 expression levels in 786-O cells transfected with siRNA targeting PTPN6. (B) Representative western blot images showing PTPN6 and GAPDH (loading control) protein levels in Ctrl-786-O and si-PTPN6-786-O cells. (C) Quantification of cell proliferation in Ctrl-786-O and si-PTPN6-786-O cells. (D) Representative images of colonies formed by Ctrl-786-O and si-PTPN6-786-O cells stained with crystal violet. (E) Quantification of colony numbers in Ctrl-786-O and si-PTPN6-786-O cells. (F) Representative images of wound healing in Ctrl-786-O and si-PTPN6-786-O cells at 0 and 24 h. (G) Quantification of the wound closure percentage in Ctrl-786-O and si-PTPN6-786-O cells. P***-value < 0.001

Article Snippet: A Human Protein Atlas-based immunohistochemical staining for PTPN6 in different cancer tissues: kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), and rectum adenocarcinoma (READ).

Techniques: Reverse Transcription, Real-time Polymerase Chain Reaction, Quantitative RT-PCR, Expressing, Transfection, Western Blot, Control, Staining

Journal: Discover Oncology

Article Title: Pan-cancer analysis of PTPN6: prognostic significance and functional implications in tumor progression

doi: 10.1007/s12672-025-03384-4

Figure Lengend Snippet: Silencing PTPN6 reduces colony formation, proliferation, and wound healing in A498 renal cancer cells. A Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR)-based quantitative analysis of PTPN6 expression levels in A498 cells transfected with siRNA targeting PTPN6. B Representative western blot images showing PTPN6 and GAPDH (loading control) protein levels in Ctrl-A498 and si-PTPN6-A498 cells. C Quantification of cell proliferation in Ctrl-A498 and si-PTPN6-A498 cells. D Representative images of colonies formed by Ctrl-A498 and si-PTPN6-A498 cells stained with crystal violet. E Quantification of colony numbers in Ctrl-A498 and si-PTPN6-A498 cells. F Representative images of wound healing in Ctrl-A498 and si-PTPN6-A498 cells at 0 and 24 h. G Quantification of the wound closure percentage in Ctrl-A498 and si-PTPN6-A498 cells. P***-value < 0.001

Article Snippet: A Human Protein Atlas-based immunohistochemical staining for PTPN6 in different cancer tissues: kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), and rectum adenocarcinoma (READ).

Techniques: Reverse Transcription, Real-time Polymerase Chain Reaction, Quantitative RT-PCR, Expressing, Transfection, Western Blot, Control, Staining

Journal: Discover Oncology

Article Title: Pan-cancer analysis of PTPN6: prognostic significance and functional implications in tumor progression

doi: 10.1007/s12672-025-03384-4

Figure Lengend Snippet: Expression and prognostic value of ptpn6 across various cancers. A TIMER2-based box plot showing PTPN6 expression levels (log2 TPM) across different cancer types and corresponding normal tissues based on TCGA data. B UALCAN-based bar plot summarizing PTPN6 expression across various TCGA cancer types, highlighting differences between tumor (red) and normal (blue) samples. C GEPIA2-based heatmap representing the differential expression of PTPN6 across cancer types, with blue indicating lower expression in tumors and red indicating higher expression compared to normal tissues. D GEPIA-based Kaplan-Meier survival curves showing the overall survival of patients with high versus low PTPN6 expression in kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), and rectum adenocarcinoma (READ) cancers. *p-value < 0.05, **p-value < 0.01, and *** p < 0.001

Article Snippet: A Human Protein Atlas-based immunohistochemical staining for PTPN6 in different cancer tissues: kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), and rectum adenocarcinoma (READ).

Techniques: Expressing, Quantitative Proteomics